%0 Journal Article
%A Burchardt, Norah A
%A Eliassen, A Heather
%A Shafrir, Amy L
%A Rosner, Bernard
%A Tamimi, Rulla
%A Kaaks, Rudolf
%A Tworoger, Shelley S
%A Turzanski-Fortner, Renée
%T Oral contraceptive use by formulation and breast cancer risk by subtype in the Nurses' Health Study II: a prospective cohort study.
%J American journal of obstetrics and gynecology
%V 226
%N 6
%@ 0002-9378
%C St. Louis, Mo.
%I Mosby
%M DKFZ-2021-03188
%P 821.e1-821.e26
%D 2022
%Z #EA:C020#LA:C020# / 2022 Jun;226(6):821.e1-821.e26
%X Oral contraceptive (OC) use has been associated with higher breast cancer risk; however, evidence on the associations between different OC formulations and breast cancer risk, especially by disease subtype, is limited.To evaluate associations between OC use by formulation and breast cancer risk by disease subtype.This prospective cohort study included 107,069 women from the Nurses' Health Study II with recalled OC use from age 13 to baseline (1989) and updated data on OC use until 2009 collected via biennial questionnaires. A total of 5,799 breast cancer cases were identified through 2017. Multivariable Cox proportional hazards models estimated hazard ratios (HR) and 95
%K breast cancer (Other)
%K epidemiology (Other)
%K estrogen (Other)
%K hormonal contraception (Other)
%K molecular subtypes (Other)
%K oral contraception (Other)
%K progestin (Other)
%K risk factors (Other)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:34921803
%R 10.1016/j.ajog.2021.12.022
%U https://inrepo02.dkfz.de/record/178190